Doug Long, VP, industry relations, IQVIA, examines shifting pharmaceutical trends, including specialty growth, biosimilar ...

Download Cerba Research's new report to discover how to overcome immunogenicity and safety challenges in oncology.

Partnership covers North America, Europe, Japan, and Australia to accelerate global access of HLX13 in immuno-oncology combinations Henlius to receive $31 million upfront, and up to $270 million in ...